| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Lyell Immunopharma, Inc. (LYEL) has 15 insiders with recent SEC Form 4 filings, including 6 buys and 2 sells. LYEL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 140.0K | $2.71M | - | |
| Dir | 130.0K | $2.51M | - | |
| Dir | 130.0K | $2.51M | - | |
| Dir | 130.0K | $2.51M | - | |
| Dir | 130.0K | $2.51M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Brawley Otis W | Director | Buy | 35,640 | $0.56 | $19,958.40 | New | -17.8% | +86.4% | |
| Mar 21, 2025 | Ramachandra Sumant | Director | Buy | 200,000 | $0.58 | $115,220.00 | New | -24.9% | +65.3% | |
| Mar 17, 2025 | Newton Charles W.66 | Chief Financial Officer | Buy | 200,000 | $0.56 | $111,620.00 | New | -1.7% | +94.7% | |
| Mar 14, 2025 | Klausner Richard73 | Director | Buy | 158,000 | $0.60 | $94,942.20 | +23.1% | -16.8% | +81.5% | |
| Mar 14, 2025 | Seely Lynn65 | President And CEO | Buy | 175,000 | $0.61 | $106,190.00 | +32.6% | -16.8% | +81.5% | |
| Aug 15, 2023 | Klausner Richard73 | Director | Sell | 58,020 | $2.28 | $132,285.60 | -5.9% | -32.3% | -47.6% | |
| Sep 23, 2022 | Klausner Richard73 | Director | Sell | 11,100 | $6.40 | $71,041.11 | -1.1% | -52.4% | -77.1% | |
| Jun 21, 2021 | Friedman Cathy | Director | Buy | 17,648 | $17.00 | $300,016.00 | New | -33.8% | -65.7% |